Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Etrolizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms HICKORY
- Sponsors Roche
- 07 Nov 2017 Planned End Date changed from 9 Jan 2019 to 26 Dec 2020.
- 07 Nov 2017 Planned primary completion date changed from 9 Jan 2019 to 26 Dec 2020.
- 01 Sep 2016 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.